Status:
COMPLETED
Use of Omega-3 Fatty Acids for Perinatal Depression
Lead Sponsor:
University of Arizona
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Depression
Depression, Postpartum
Eligibility:
FEMALE
18-45 years
Phase:
PHASE2
Brief Summary
This study will evaluate the effectiveness of using omega-3 fatty acids to treat women with perinatal depression.
Detailed Description
Depression is the chief cause of disease-associated disability in women. Because of the highs and lows during pregnancy through the first year of motherhood, expectant and new mothers are particularly...
Eligibility Criteria
Inclusion
- Women who are pregnant (12 to 32 weeks gestation) or postpartum
- Meets criteria for a major depressive episode
- Scores a minimum of 9 on the Edinburgh Postnatal Depression scale
- Must be able to be treated on an outpatient basis
Exclusion
- Known intolerance or allergy to omega-3 fatty acid or fish oil
- Presently taking antidepressant medication
- Currently using heparin or warfarin (compounds used to prevent blood from clotting)
- Presence of psychotic symptoms
- History of mania (abnormally elevated mood state) or hypomania (same as mania but occurs at a much lesser degree)
- Active suicidal ideation (desire to commit suicide)
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00402389
Start Date
June 1 2004
End Date
January 1 2006
Last Update
March 29 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Women's Mental Health Program; University of Arizona; Department of Psychiatry
Tucson, Arizona, United States, 85724